1994
DOI: 10.1016/0002-9149(94)90905-9
|View full text |Cite
|
Sign up to set email alerts
|

Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
90
0
9

Year Published

1998
1998
2015
2015

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 130 publications
(106 citation statements)
references
References 24 publications
7
90
0
9
Order By: Relevance
“…25) In CHF patients, renal blood flow and eGFR are decreased 24) and the erythropoietin level is increased with the severity of heart failure. 26) However, this increase could not raise hemoglobin to levels high enough to obtain adequate oxygenation for CHF patients, and ESAs were used for the therapeutic target in CHF patients with anemia. Although some studies using ESAs performed in single center trials showed improvement of NYHA functional class and echocardiographic data in CHF patients with anemia, 6,7) the latest multicenter randomized, double blind, placebo-controlled trial did not yield the expected results.…”
Section: Discussionmentioning
confidence: 99%
“…25) In CHF patients, renal blood flow and eGFR are decreased 24) and the erythropoietin level is increased with the severity of heart failure. 26) However, this increase could not raise hemoglobin to levels high enough to obtain adequate oxygenation for CHF patients, and ESAs were used for the therapeutic target in CHF patients with anemia. Although some studies using ESAs performed in single center trials showed improvement of NYHA functional class and echocardiographic data in CHF patients with anemia, 6,7) the latest multicenter randomized, double blind, placebo-controlled trial did not yield the expected results.…”
Section: Discussionmentioning
confidence: 99%
“…This occurs because treatment with ACE inhibitors is associated with higher recombinant human Epo (rhEpo) requirements (whereas withdrawal of ACE inhibitors decreases rhEpo doses), reflecting the direct effect of angiotensin II on erythropoiegenesis (89). Exceptions to the link of renin-angiotensin system activation and increased hematocrit are often cases in which increment of red blood cells mass are masked by volume expansion (i.e., in patients with severe heart failure) (90).…”
Section: Interplay Of Renin-angiotensin and Epo Systemsmentioning
confidence: 99%
“…Particularly, these studies have shown a possible involvement of the renin angiotensin system in the genesis of erythrocytosis observed following a kidney transplant 191 or in association with congestive heart failure, 192 chronic obstructive pulmonary disease, 193,194 essential, malignant, or renovascular hypertension [195][196][197] or with chronic hemodialysis. 198,199 The pathogenesis of erythrocytosis observed in these conditions is complex in that erythropoietin, angiotensin II and insulin-like growth factor I are all involved.…”
Section: Apoptotic Mechanisms In the Genesis Of Erythrocytosis Associmentioning
confidence: 99%